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Transcatheter Valve) trial, we examined outcomes stratiﬁed according to diabetes status of patients randomly
assigned to receive transcatheter or surgical AVR. The primary outcome was all-cause mortality at 1 year.Results Among 657 patients enrolled in PARTNER who underwent treatment, there were 275 patients with diabetes
(145 transcatheter, 130 surgical). There was a signiﬁcant interaction between diabetes and treatment group for
1-year all-cause mortality (p ¼ 0.048). Among diabetic patients, all-cause mortality at 1 year was 18.0% in the
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among nondiabetic patients, there was no signiﬁcant difference in all-cause mortality at 1 year (p ¼ 0.48). Among
diabetic patients, the 1-year rates of stroke were similar between treatment groups (3.5% transcatheter vs. 3.5%
surgery; p ¼ 0.88), but the rate of renal failure requiring dialysis >30 days was lower in the transcatheter group (0%
vs. 6.1%; p ¼ 0.003).Conclusions Among patients with diabetes and severe symptomatic AS at high risk for surgery, this post-hoc stratiﬁed analysis
of the PARTNER trial suggests there is a survival beneﬁt, no increase in stroke, and less renal failure from
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1091Diabetes mellitus adversely affects morbidity and mortality
for all types of cardiovascular diseases (1,2). In patients with
aortic stenosis (AS), diabetes is associated with increased
hypertrophic remodeling, decreased left ventricular function,
and worse heart failure symptoms (3,4). Diabetes has also
been associated with increased morbidity and mortality after
surgical aortic valve replacement, even after adjustment for
comorbidities such as vascular disease and renal dysfunctionSee page 1110
KCCQ = Kansas City
Cardiomyopathy
Questionnaire(5,6). The mechanisms for this additional surgical risk are
not completely known, although it is hypothesized that
the inﬂammation, oxidative stress, and reperfusion injury
induced by cardioplegia and cardiopulmonary bypass are
particularly harmful in the setting of diabetes and hyper-
trophic ventricular remodeling from chronic pressure
overload due to AS, thereby causing adverse short- and
long-term consequences (7–13). As such, a less-invasive
method of valve replacement that avoids the injurious
effects of cardiopulmonary bypass may lead to improved
clinical outcomes among these high-risk patients with
diabetes. Accordingly, we examined the clinical outcomes of
patients at high risk for surgery enrolled in the PARTNER
(Placement of Aortic Transcatheter Valve) trial to evaluate
whether outcomes varied according to diabetes status after
treatment with transcatheter versus surgical aortic valve
replacement (14).
Methods
Study population. The design, inclusion and exclusion
criteria, and primary results of the high-risk cohort (cohort A)
of the PARTNER trial have been reported (14). These
patients were at high surgical risk as deﬁned by a predicted risk
of death 15% by 30 days after surgery. After evaluation of
vascular anatomy, patients were included in either the trans-
femoral placement cohort or the transapical placement cohort
and randomized to undergo transcatheter therapy with the
Edwards SAPIEN heart valve system (Edwards Lifesciences,
Irvine, California) or surgical aortic valve replacement. Some
patients did not undergo their assigned procedure due to
death, refusal, study withdrawal, and/or pre-treatment clinical
deterioration. For the current analysis, we included onlya member of the PARTNER trial steering committee and consultant for Edwards
Lifesciences, a member of the steering committee for the Portico trial (St. Jude
Medical), and a member of the scientiﬁc advisory board of Thubrikar Aortic Valve.
Dr. Thourani is a member of the PARTNER trial steering committee; and is
a consultant for Edwards Lifesciences, Sorin Medical, St. Jude Medical, and
DirectFlow. Dr. Waksman is a member of the Speakers’ Bureau of Boston Scientiﬁc,
Medtronic, AstraZeneca, Biotronik, and Abbott Vascular. Drs. Tuzcu, Svensson,
Smith, and Leon are unpaid members of the PARTNER Executive Committee; and
has received travel reimbursements from Edwards Lifesciences for activities related to
these positions. All other authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
Manuscript received August 7, 2013; revised manuscript received October 11, 2013,
accepted October 17, 2013.patients who were randomized to
and received the assigned treat-
ment (as-treated population). The
diagnosis of diabetes and other
clinical characteristics were deter-
mined by the enrolling sites. The
study protocol was approved by
the institutional review board at
each enrolling site, and all pati-
ents provided written informed
consent.
Clinical endpoints. Clinical events, including death (all-
cause and cardiac), repeat hospitalizations, stroke, renal
failure, major bleeding, myocardial infarction, and vascular
complications, were adjudicated by a clinical events
committee. The primary endpoint of the PARTNER trial
and our analysis was all-cause death at 1 year. A detailed
report of the classiﬁcation of deaths among the diabetic and
nondiabetic patients treated with transcatheter or surgical
aortic valve replacement in the transfemoral and transapical
placement cohorts is provided in Online Table 1. Repeat
hospitalizations were deﬁned as hospitalization resulting
from symptoms of AS (valve-related deterioration, including
heart failure, angina, or syncope) or complications of the
valve procedure. Stroke was deﬁned as a focal neurological
deﬁcit lasting 24 h or a focal neurological deﬁcit
lasting <24 h with imaging ﬁndings of acute infarction or
hemorrhage. Renal failure events were deﬁned as the need
for dialysis of any sort (hemodialysis, continuous venovenous
hemodialysis, peritoneal). Further details on clinical events
deﬁnitions are provided in Online Table 2. Many of these
clinical event deﬁnitions are consistent with the VARC-2
(Valve Academic Research Consortium–2) deﬁnitions
(e.g., cardiac death, stroke, myocardial infarction), but others
differ substantially (e.g., renal failure, major bleeding) (15).
An independent core laboratory analyzed all echocardio-
grams (16). The presence and severity of post-procedural
prosthesis–patient mismatch and aortic regurgitation were
determined according to VARC-2 criteria (15). The Kansas
City Cardiomyopathy Questionnaire (KCCQ), a disease-
speciﬁc health status measure of heart failure, was used to
assess health status (17,18).
Statistical analysis. Continuous variables are summarized as
mean SD or median (quartile), and they were compared by
using the Student t test or Mann-Whitney rank sum test as
appropriate. Categorical variables were compared by using the
chi-square or Fisher exact test. Survival curves for time-to-
event variables, based on all available follow-up data, were
performed with the use of Kaplan-Meier estimates and were
compared between groups with the use of the log-rank test.
Cox proportional hazards models were used to calculate
hazard ratios (HRs) and to test for interactions. KCCQoverall
summary scores were compared by using analysis of covariance
to adjust for baseline differences in KCCQ scores between
groups. All statistical analyses were performed by using SAS
version 9.2 (SAS Institute, Inc., Cary, North Carolina).
Table 1
Clinical Characteristics of the Diabetic Subjects in the
High-Risk Cohort of the PARTNER Trial
TAVR-DM
(n ¼ 145)
SAVR-DM
(n ¼ 130) p Value
Demographic and clinical data
Age (yrs) 81.8  7.5 82.4  6.8 0.47
Female 35% 39% 0.57
Body mass index (kg/m2) 30.1  7.7 28.8  6.6 0.13
Body surface area 1.93  0.24 1.89  0.23 0.20
STS score 12.2  3.4 11.8  3.1 0.31
STS score >10 80% 80% 1.00
Logistic EuroSCORE 28.3  16 28.3  16 0.99
Hyperlipidemia 86% 86% 0.99
Smoking 55% 55% 0.88
Hypertension 95% 95% 0.73
NYHA functional class IV 55% 57% 0.68
Angina 29% 22% 0.21
Coronary disease 82% 84% 0.70
Previous myocardial infarction 29% 30% 0.88
Previous percutaneous
coronary intervention
35% 35% 0.95
Previous coronary artery
bypass surgery
51% 54% 0.64
Stroke or TIA (last 6–12 months) 30% 32% 0.70
Carotid disease 32% 27% 0.40
Peripheral vascular disease 48% 43% 0.41
Porcelain aorta 0.7% 0.0% 1.00
Pulmonary hypertension 44% 45% 0.89
Major arrhythmia 40% 49% 0.16
Permanent pacemaker 26% 28% 0.68
Renal disease
(creatinine 2 mg/dl)
23% 26% 0.60
Liver disease 3.4% 3.1% 0.43
Chronic obstructive
lung disease
48% 42% 0.26
Oxygen dependent 9% 9% 0.94
Anemia 74% 64% 0.10
Transfemoral cohort 71% 68% 0.55
Baseline cardiac medications
Beta-blockers 68% 67% 0.91
ACE inhibitors 40% 39% 0.79
ARBs 16% 22% 0.17
ACE inhibitors or ARBs 52% 57% 0.45
Calcium-channel blockers 26% 22% 0.44
Statins 73% 65% 0.13
Diuretics 76% 68% 0.13
Nitrates 15% 10% 0.26
Antiarrhythmics 26% 30% 0.41
Aspirin 77% 61% 0.003
Antiplatelet (other than aspirin) 26% 23% 0.64
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; DM ¼ diabetes
mellitus; NYHA ¼ New York Heart Association; PARTNER ¼ Placement of Aortic Transcatheter
Valve; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgery; TAVR ¼
transcatheter aortic valve replacement; TIA ¼ transient ischemic attack.
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Patient population. Among the 699 patients enrolled in
the PARTNER trial cohort A, 657 patients were random-
ized to and received transcatheter or surgical therapy; 313patients were treated with surgery and 344 patients were
treated with transcatheter therapy. Among the as-treated
population, 275 (42%) patients had diabetes, 145 in the
transcatheter group (103 transfemoral, 42 transapical) and
130 in the surgery group (88 transfemoral, 42 transapical
cohort). Among the 382 patients without diabetes, 199 were
treated with transcatheter valve replacement (137 trans-
femoral, 62 transapical) and 183 were treated with surgery
(133 transfemoral, 50 transapical).
The clinical characteristics and medication usage of
patients in the trial with and without diabetes differed in
ways that would be expected based on diabetes status
(Online Table 3). Within each subgroup of patients (dia-
betic and nondiabetic), the clinical characteristics were
generally well matched between those who received trans-
catheter versus surgical valve replacement (Table 1, Online
Table 4).
Diabetic patients. Stratiﬁed analyses based on diabetes
status were performed for several important clinical outcomes
at 1 year. There was a signiﬁcant interaction between diabetes
status and all-cause mortality (interaction p¼ 0.048) (Fig. 1).
Among the patients with diabetes, 1-year all-cause mortality
was 18.0% in transcatheter-treated patients versus 27.4%
in the surgically treated patients (HR: 0.60 [95% conﬁdence
interval (CI): 0.36 to 0.99]; p ¼ 0.044) (Figs. 1 and 2A).
The Kaplan-Meier survival curves for the transfemoral
placement cohort (Fig. 2B) and the transapical placement
cohort (Fig. 2C) demonstrate a consistent relationship of
lower all-cause mortality for transcatheter-treated versus
surgically treated diabetic patients compared with the overall
population of diabetic patients (Fig. 2A).
At 6months, all-causemortality was lower in transcatheter-
treated diabetic patients compared with surgically treated
diabetic patients (10.3% vs. 23.4%; HR: 0.41 [95% CI: 0.22
to 0.76]; p ¼ 0.003) (Fig. 2A). At 2 years, the survival
beneﬁt observed at 6 months and 1 year from transcatheter
treatment compared with surgical treatment in diabetic
patients was no longer signiﬁcant (HR: 0.76 [95% CI: 0.49
to 1.19]; p ¼ 0.23) (Online Fig. 1A).
The rates of stroke were similar between transcatheter-
treated and surgically treated diabetic patients at 30 days
(3.5% vs. 2.4%; p ¼ 0.58) and 1 year (3.5% vs. 3.5%;
p ¼ 0.88) (Table 2). At 1 year, there was a decreased rate of
renal failure requiring dialysis with transcatheter therapy
compared with surgical therapy (4.2% vs. 10.6%; p ¼ 0.05),
particularly dialysis lasting >30 days (0.0% vs. 6.1%;
p ¼ 0.003). Similar to the main trial results, there was an
increased risk of major bleeding with surgery among diabetic
subjects but an increased risk of major vascular complications
with transcatheter therapy at 30 days and 1 year (p < 0.05
for all relationships).
In terms of echocardiographic symptoms and labora-
tory ﬁndings, the incidence of post-operative mild and
moderate or severe total aortic regurgitation was higher
in diabetic patients treated with transcatheter therapy
compared with surgery (Table 3). There was a trend toward
Figure 1 Clinical Outcomes Stratiﬁed by Diabetes in the High-Risk Cohort of the PARTNER Trial
Cox proportional hazards models were used to evaluate the hazard ratios for patients with diabetes mellitus (DM) and without diabetes mellitus (NDM) for the clinical outcomes
shown and the interaction between diabetes status and treatment for each clinical outcome. CI ¼ conﬁdence interval; PARTNER ¼ Placement of Aortic Transcatheter Valve;
SAVR ¼ surgical aortic valve replacement; TA ¼ transapical; TAVR ¼ transcatheter aortic valve replacement; TF ¼ transfemoral.
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mismatch at 30 days with transcatheter therapy, whereas left
ventricular mass was lower at 30 days in surgically treated
patients. A lower incidence of New York Heart Association
functional class III or IV heart failure symptoms, better
quality of life, and longer 6-min walk distance were observed
at 30 days in diabetic patients treated with transcatheter
therapy compared with those receiving surgery; there were no
signiﬁcant between-group differences at 6 months or 1 year
(Table 4). Post-procedural troponin levels and white blood cell
counts were higher in diabetic subjects treated with surgery
compared with those receiving transcatheter therapy (Table 3).
Nondiabetic patients. There was no difference in 1-year
all-cause mortality in nondiabetic subjects treated with
transcatheter versus surgical therapy (Figs. 3A and 3B);
however, there was a trend toward increased mortality in the
transapical placement cohort from transcatheter therapy
compared with surgery (Fig. 3C). A trend toward a higher
risk of stroke was observed in nondiabetic patients treated
with transcatheter therapy compared with those receiving
surgery at 1 year (7.6% vs. 2.8%; HR: 2.60 [95% CI: 0.94 to
7.22]; p¼ 0.056) (Fig. 1). The rates of repeat hospitalizationand renal failure among nondiabetic patients were similar in
the 2 treatment groups. At 2 years, there was also no differ-
ence in all-cause mortality in nondiabetic subjects treated
with transcatheter versus surgical therapy (Online Fig. 2).Discussion
We report for the ﬁrst time, in a post-hoc stratiﬁed analysis
of the high-risk patients enrolled in the PARTNER
trial, a differential response to transcatheter versus sur-
gical treatment based on diabetes status. Although the
PARTNER trial demonstrated similar rates of death at 1
year in those treated with transcatheter or surgical therapy
for the overall population, we found that diabetic patients
who were treated with transcatheter aortic valve replacement
had a 9% lower absolute risk of 1-year all-cause mortality
and a 40% lower hazard of death over the ﬁrst year after the
procedure compared with diabetic patients treated with
surgical valve replacement. Furthermore, diabetic patients
treated with transcatheter therapy had a similar rate of stroke
and lower incidence of renal failure compared with those
treated with surgery. These ﬁndings have important clinical
Figure 2
Time-to-Event Curves for Diabetic Patients for
1-Year Death From Any Cause
One-year time-to-event curves are shown for diabetic patients for death from any
cause in the as-treated population of the PARTNER trial (treated with either TAVR or
SAVR). The curves are shown for (A) all diabetic patients, (B) those in the TF
cohort, and (C) those in the TA cohort. The event rates were calculated by using
the Kaplan-Meier methods and compared with the use of the log-rank test.
HR ¼ hazard ratio; other abbreviations as in Figure 1.
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1094implications for the treatment of patients with severe AS
and diabetes who are at high risk for surgery.
Clinical implications. Both transcatheter and surgical valve
replacement relieve left ventricular pressure overload from
AS by treating the mechanical obstruction of the valve.
Among the overall population, the PARTNER trial dem-
onstrated that survival at 1 year was similar with transcatheter
and surgical valve replacement for patients with severe
symptomatic AS at high risk for surgery. However, there may
be subgroups of patients who will do better with 1 approach
than the other. As we gain more experience with these 2
treatment options, we will learn how to individualize treat-
ment strategies based on a variety of potential factors to
obtain the best clinical results. Our study raises the intriguing
possibility that transcatheter valve replacement may be the
preferred approach for diabetic patients with severe symp-
tomatic AS who are at high surgical risk.
There is considerable interest in comparing less-invasive
transcatheter or percutaneous therapies with surgery for
a variety of cardiovascular problems, including valve disease
and coronary, aortic, carotid, and peripheral vascular disease,
particularly in diabetic patients (19–23). These comparisons
involve differences both in which therapy is provided (e.g.,
stent vs. bypass graft) and how it is provided (e.g., catheter-
based vs. open surgery). When comparing transcatheter
versus surgical aortic valve replacement, there is relatively little
difference in which therapy is provided. In both cases, the
mechanical valve obstruction is treated by the placement of
a new valve that relieves the pressure overload on the ventricle.
Nonetheless, differences in how well the implanted valve
opens the previously restricted oriﬁce (effective oriﬁce area)
and howmuch it leaks could affect outcomes. In contrast, there
are more obvious differences in how the therapy is provided,
which we suspect underlies the difference in survival among
diabetic patients between the 2 treatment groups. In the case
of a transcatheter approach, there is rapid ventricular pacing
with large sheaths introduced into the major vessels and/or
heart, whereas with surgery, there are the injurious effects of
cardiopulmonary bypass, cardioplegia, and reperfusion.
Among diabetic patients, the survival curves between the
transcatheter and surgical treatment groups separated soon
after valve replacement and continued to diverge until
approximately 6 months, after which the curves moved
modestly toward each other; by 2 years, there was no
signiﬁcant difference in survival between the 2 treatment
groups. We hypothesize that this relationship is due to the
short-term beneﬁt of a less-invasive approach to replace the
valve that avoids cardiopulmonary bypass, which is miti-
gated over time by nonprocedure-related factors and the
known deleterious effects of increased aortic regurgitation
after transcatheter valve replacement. In the PARTNER
trial, both in the whole population and the subgroup with
diabetes, there was a much greater incidence of mild,
Table 2 Clinical Outcomes in Diabetic Patients in the High-Risk Cohort of the PARTNER Trial
TAVR-DM
Patients
(n ¼ 145)
SAVR-DM
Patients
(n ¼ 130)
Hazard Ratio
(95% CI) p Value
30 days
Death (all-cause) 3.4% (5) 6.2% (8) 0.56 (0.18–1.70) 0.29
Death (all-cause), TF cohort 1.9% (2) 6.9% (6) 0.28 (0.06–1.39) 0.09
Death (all-cause), TA cohort 7.1% (3) 4.8% (2) 1.51 (0.25–9.07) 0.65
Death (cardiac) 1.4% (2) 3.2% (4) 0.44 (0.08–2.42) 0.33
Repeat hospitalizations 5.0% (7) 8.0% (10) 0.61 (0.23–1.60) 0.31
Stroke (any) 3.5% (5) 2.4% (3) 1.50 (0.36–6.27) 0.58
Major bleeding 11.1% (16) 22.3% (29) 0.48 (0.26–0.88) 0.01
Vascular complications (major) 11.7% (17) 2.3% (3) 5.10 (1.50–17.4) 0.003
Myocardial infarction 0.0% (0) 0.8% (1) d 0.29
Renal failure (dialysis required) 3.5% (5) 7.8% (10) 0.44 (0.15–1.30) 0.12
Dialysis lasting >30 days 0.0% (0) 3.2% (4) d 0.03
1 year
Death (all-cause) 18.0% (26) 27.4% (35) 0.60 (0.36–0.99) 0.04
Death (all-cause), TF cohort 16.7% (17) 24.4% (21) 0.61 (0.32–1.16) 0.13
Death (all-cause), TA cohort 21.4% (9) 33.6% (14) 0.59 (0.26–1.37) 0.22
Death (cardiac) 8.0% (11) 8.3% (10) 0.89 (0.38–2.11) 0.80
Repeat hospitalizations 19.3% (26) 13.7% (16) 1.32 (0.71–2.45) 0.39
Stroke (any) 3.5% (5) 3.5% (4) 1.11 (0.30–4.12) 0.88
Major bleeding 15.1% (21) 26.9% (34) 0.52 (0.30–0.89) 0.01
Vascular complications (major) 11.7% (17) 2.3% (3) 5.10 (1.50–17.4) 0.003
Myocardial infarction 0.0% (0) 0.8% (1) d 0.29
Renal failure (dialysis required) 4.2% (6) 10.6% (13) 0.39 (0.15–1.03) 0.05
Dialysis lasting >30 days 0.0% (0) 6.1% (7) d 0.003
Values are % (n) unless otherwise indicated. The event rates were calculated with the use of Kaplan-Meier methods.
CI ¼ conﬁdence interval; TA ¼ transapical; TF ¼ transfemoral; other abbreviations as in Table 1.
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1095moderate, and severe aortic regurgitation in the trans-
catheter treatment group compared with surgery, which is
associated with increased all-cause mortality (24). A
potential implication is that if the incidence of aortic
regurgitation after transcatheter aortic valve replacement is
reduced, the early substantial survival beneﬁt of trans-
catheter valve replacement in diabetic patients may be sus-
tained beyond the ﬁrst year.
Other observations from this analysis merit further study.
Although not the focus of our analysis, the rate of all-cause
mortality at 1 year was lower in diabetic patients compared
with nondiabetic patients treated with transcatheter therapy.
Diabetes is known to adversely affect morbidity and mortality
for all types of cardiovascular disease and adversely inﬂuence
post-procedural outcomes after percutaneous and surgical
procedures (1,2,25,26). As such, this result was somewhat
surprising. However, it should be noted that there were
numerous baseline clinical differences between the diabetic
and nondiabetic patients (Online Table 3), which could
confound this comparison. In particular, diabetic patients had
a much larger body mass index than nondiabetic patients,
which was expected. In the PARTNER trial, higher body
mass index had an independent protective effect in the
transcatheter group but not in the surgical group. This ﬁndingmay explain, at least in part, the unexpected observation of
lower mortality in diabetic patients compared with nondiabetic
patients in the transcatheter group. This hypothesis-
generating observation of an apparent “diabetes paradox” re-
quires further study and careful adjustment for confounders.
Possible mechanisms. Diabetes is characterized by a milieu
of hyperglycemia, insulin resistance, and increased nonester-
iﬁed fatty acids, which contribute to oxidative stress, lip-
otoxicity, advanced glycation end products, and altered
calcium handling and substrate metabolism (11). Surgical
valve replacement involves cardioplegia, cardiopulmonary
bypass, and reperfusion injury, which may cause more
inﬂammation, oxidative stress, and myocardial ischemia/
injury thanwith the rapid ventricular pacing performed during
transcatheter therapy (7–10,12,13). In patients with diabetes,
this can intensify an already existing deleterious myocardial
and systemic environment, which may have important short-
and long-term adverse consequences for cardiac performance
and clinical outcomes after valve replacement. Recently,
Sinning et al. (27) demonstrated that the development of
systemic inﬂammatory response syndrome during the ﬁrst 48
h after transcatheter aortic valve replacement is associatedwith
increased 30-day and 1-year mortality. We speculate that
surgical valve replacementmay be associatedwith an increased
Table 3
Echocardiographic and Laboratory Data in Diabetic Patients in the High-Risk Cohort
of the PARTNER Trial
TAVR-DM SAVR-DM p Value
Echocardiography
Ejection fraction
Baseline 51.7  14.0 52.7  11.7 0.53
30 days 54.1  11.1 53.7  10.8 0.78
LV mass
Baseline 304  86 289  88 0.18
30 days 294  86 256  78 0.002
Prosthesis–patient mismatch
(moderate or severe) 30 days*
46.9% 60.7% 0.07
Moderate/severe mitral regurgitation
Baseline 14.2% 15.6% 0.75
30 days 15.4% 14.6% 0.86
Mild total aortic regurgitation
Baseline 48.9% 35.2% 0.02
30 days 52.8% 9.3% <0.0001
6 months 54.1% 5.5% <0.0001
Moderate/severe total aortic regurgitation
Baseline 6.4% 13.6% 0.05
30 days 9.6% 1.0% 0.007
6 months 9.0% 1.4% 0.052
Laboratory values
Troponin I
Baseline 0.04 (0.02, 0.08) 0.05 (0.03, 0.10) 0.12
24 h post-procedure 0.78 (0.20, 3.62) 4.47 (2.04, 10.40) <0.001
Creatinine
Baseline 1.30 (1.00, 1.60) 1.25 (1.00, 1.60) 0.85
30 days 1.21 (1.00, 1.59) 1.29 (0.94, 1.84) 0.80
White blood cells
Baseline 6.9 (5.9, 8.2) 6.7 (5.7, 8.1) 0.35
24 h post-procedure 10.2 (8.6, 12.4) 11.7 (9.9, 15.4) 0.056
30 days 7.0 (6.0, 8.0) 7.3 (6.2, 9.8) 0.04
Hemoglobin
Baseline 11.6 (10.7, 12.8) 11.9 (10.6, 13.0) 0.40
24 h post-procedure 10.0 (9.2, 11.1) 9.9 (8.8, 11.4) 0.89
30 days 11.2 (10.5, 12.1) 11.0 (10.0, 11.9) 0.13
Values are mean  SD, %, or median (25th, 75th percentiles) and includes all subjects with data at the speciﬁed time. *Patient–prosthesis mismatch
(moderate or severe) ¼ effective oriﬁce area index 0.85 cm2/m2.
LV ¼ left ventricular; other abbreviations as in Table 1.
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compared with transcatheter replacement. Consistent with
this possibility, the 24-h post-procedure blood analyses drawn
in the PARTNER trial showed higher levels of white blood
cells in patients with diabetes after surgical aortic valve
replacement compared with transcatheter valve replacement.
The 24-h post-procedure cardiac enzyme levels were also
higher in the diabetic patients treated with surgery, suggesting
increased ischemic injury compared with a transcatheter
approach. Other mechanisms whereby transcatheter therapy
may confer a survival beneﬁt in diabetic patients include less
prosthesis–patient mismatch and less post-procedural renal
failure requiring dialysis, both of which have a known adverse
impact on clinical outcomes (16,24). However, ultimately themechanisms underlying the survival beneﬁt from a trans-
catheter valve replacement in diabetic patients require further
investigation. These mechanisms include the impact of
insulin and/or oral diabetic medical treatments and how the
metabolic syndrome and diabetes separately and in combi-
nation inﬂuence outcomes in diabetic patients undergoing
transcatheter or surgical valve replacement.
Study limitations. One limitation of our study was that
diabetes status was not a pre-speciﬁed subgroup analysis. As
such, these results should be considered hypothesis-
generating and need to be conﬁrmed in future research.
However, given the relatively low power to demonstrate
superiority of transcatheter replacement over surgical
replacement in a subgroup analysis, the statistically signiﬁcant
Table 4
Symptoms, Quality of Life, and 6-Min Walk Distance in Diabetic Patients in the
High-Risk Cohort of the PARTNER Trial
TAVR-DM SAVR-DM p Value
NYHA functional class III/IV
Baseline 95% 94% 0.63
Discharge/7 days 40% 60% 0.003
30 days 21% 40% 0.002
6 months 18% 11% 0.18
1 year 13% 10% 0.58
KCCQ
Baseline
Subjects with KCCQ data 139 120
Overall summary score 39.5  23.1 44.3  20.3 0.08
30 days
Subjects with KCCQ data 123 100
Overall summary score adjusted for baseline score 64.9 (60.6, 69.2) 55.3 (50.4, 60.1) 0.004
6 months
Subjects with KCCQ data 118 87
Overall summary score adjusted for baseline score 68.9 (64.7, 73.0) 72.3 (67.5, 77.1) 0.29
1 year
Subjects with KCCQ data 108 83
Overall summary score adjusted for baseline score 68.2 (64.0, 72.3) 72.7 (67.8, 77.6) 0.17
6-min walk distance
Baseline
Could not perform 41% 39% 0.81
Distance walked (m)* 175  116 180  103 0.77
30 days
Could not perform 42% 50% 0.19
Distance walked (m)* 208  111 159  97 0.01
6 months
Could not perform 35% 32% 0.60
Distance walked (m)* 238  115 236  115 0.92
1 year
Could not perform 28% 32% 0.47
Distance walked (m)* 190  98 226  113 0.06
Values are %, mean  SD, or median (25th, 75th percentiles). *Excluding those who could not perform the 6-min walk.
KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; other abbreviations as in Table 1.
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evaluation. Second, the diagnosis of diabetes was determined
by enrolling sites and was not veriﬁed by using other mech-
anisms. However, the differences observed between diabetic
and nondiabetic patients in the PARTNER trial with respect
to baseline clinical characteristics and medication usage are
consistent with those that would be expected based on the
presence or absence of diabetes. Furthermore, we did not have
reliable information on diabetic medication usage (insulin
and/or oral medications) or access to data on the severity or
duration of diabetes, microvascular complications, or glucose
control. How each of these factors contributes to the treat-
ment effect of transcatheter versus surgical aortic valve
replacement will require further study. However, by including
patients with mild (recent onset, diet controlled, or oral
medications only) as well as severe (long-standing, requiring
insulin) diabetes, we were less likely to disprove the nullhypothesis that survival would be similar between the trans-
catheter and surgical treatment groups.
Conclusions
Diabetes is associated with increased morbidity and mortality
in patients with AS undergoing surgical valve replacement. In
a post-hoc stratiﬁed analysis of the PARTNER trial in which
high-risk patients were randomized to undergo transcatheter
or surgical aortic valve replacement, we found that diabetic
patients had a survival beneﬁt at 1 year with no increased risk
of stroke and less renal failure when treated with transcatheter
valve replacement compared with surgery. These results
suggest that transcatheter aortic valve replacement may be the
preferred treatment approach for patients with AS and dia-
betes who are at high risk for surgery. Conﬁrmation of these
ﬁndings, particularly in lower-risk populations, is needed, as
Figure 3
Time-to-Event Curves for Nondiabetic Patients for
1-Year Death From Any Cause
One-year time-to-event curves are shown for nondiabetic patients for death from
any cause in the as-treated population of the PARTNER trial (treated with either
TAVR or SAVR). The curves are shown for (A) all patients without diabetes, (B)
those in the TF cohort, and (C) those in the TA cohort. The event rates were
calculated by using the Kaplan-Meier methods and compared with the use of the
log-rank test. Abbreviations as in Figures 1 and 2.
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1098well as insights into the underlying mechanisms for the
observed survival beneﬁt.Reprint requests and correspondence: Dr. Brian R. Lindman,
Cardiovascular Division, Washington University School of Medi-
cine, Campus Box 8086, 660 South Euclid Avenue, St. Louis,
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